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Abstract
Background—Frequent blood pressure (BP) measurements are necessary to ensure patient 
safety during hemodialysis (HD) treatments. Intradialytic BPs are not optimal diagnostic tools for 
hypertension and cardiovascular risk stratification, but they do have critical clinical and prognostic 
significance. We present evidence associating intradialytic BP phenomena including fall, rise, and 
variability with adverse clinical outcomes and review related pathophysiologic mechanisms and 
potential management strategies.
Summary—Observational studies demonstrate associations between intradialytic hypotension, 
hypertension, and BP variability and mortality. Lack of consensus regarding diagnostic criteria has 
hampered data synthesis, and prospective studies investigating optimal management strategies for 
BP phenomena are lacking. Mechanistic data suggest that cardiac, gut, kidney, and brain ischemia 
may lie on the causal pathway between intradialytic hypotension and mortality, and endothelial 
cell dysfunction, among other factors, may be an important mediator of intradialytic hypertension 
and adverse outcomes. These plausible pathophysiologic links present potential therapeutic targets 
for future inquiry. The phenomenon of intradialytic BP variability has not been adequately 
studied, and practical clinical measures and treatment strategies are lacking.
Key Messages—Intradialytic BP phenomena have important prognostic bearing. Clinical 
practice guidelines for both intradialytic hypotension and hypertension exist, but their underlying 
evidence is weak overall. Further research is needed to develop consensus diagnostic criteria for 
intradialytic hypotension, hypertension and BP variability and to elucidate optimal treatment and 
prevention strategies for each BP manifestation.
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Blood pressure (BP) measurement is a fundamental part of hemodialysis (HD) 
administration with measurements taken before and after HD and at frequent intervals 
during treatments. It is well-recognized that these peridialytic and intradialytic BP 
measurements are poorly reflective of interdialytic BP behavior and overall cardiovascular 
disease burden.[1–3] However, such BP measurements are essential for monitoring patient 
safety during dialysis. Peridialytic BPs and adverse clinical outcomes have a well-described 
“U”-shaped association,[4,5] but no prospective studies have established optimal 
intervention thresholds on either end of the BP spectrum. Overt intradialytic BP 
abnormalities such as hypotension in a pale, diaphoretic patient or hypertension in a patient 
with headache and vision change are impossible to ignore. Such drastic presentations spark 
immediate intervention, and elegant studies demonstrating harm are not needed. While these 
extreme BP events occur more often than desired, they are relatively infrequent in today’s 
era of bicarbonate-based dialysate and volumetric ultrafiltration (UF).
Instead, the clinical dilemmas and prognostic uncertainties lie along a spectrum of 
seemingly minor and often asymptomatic intradialytic BP falls, elevations, and fluctuations. 
Such uncertainties stem from lack of consensus definitions for intradialytic hypotension, 
hypertension and BP variability and the paucity of evidence on effective intervention and 
prevention strategies. These evidence limitations combined with absence of associated 
symptoms contribute to the tendency to conflate asymptomatic BP fluctuations with 
“normal” BP. However, growing evidence suggests harm from aberrant, asymptomatic 
intradialytic BP changes. Currently, a hierarchy exists with regards to the volume and 
quality of existing literature. Intradialytic hypotension has both the largest and strongest 
clinical evidence-base, followed by intradialytic hypertension and intradialytic BP 
variability respectively. Herein, we review evidence associating different intradialytic BP 
phenomena, including BP fall, rise and variability, with adverse clinical outcomes, 
summarize their pathophysiology and management, and identify uncertainties requiring 
further research.
DIALYSIS UNIT BLOOD PRESSURE MEASUREMENTS
Clinicians have a plethora of BP measurements available when caring for in-center, thrice-
weekly, maintenance HD patients. The most abundant measurements are peridialytic BPs, 
measurements taken before and after HD, and intradialytic BPs, measurements assessed at 
frequent intervals during HD. Despite their accessibility, peridialytic and intradialytic BPs 
are limited in their diagnostic capacity. Ambulatory and home BP measurements are more 
reliable for diagnosing hypertension and performing cardiovascular risk stratification than 
peridialytic BPs.[2,6,7] Technical, patient, and HD procedural factors thwart in-center BP 
diagnostic accuracy. In a study comparing BP measurement techniques, Rahman et al. 
demonstrated BP over-estimation with HD machine automated measurements compared to 
BPs taken by a sphygmomanometer operated in accordance with American Heart 
Association guidelines.[8] Numerous potential sources for error in machine-measured BPs 
exist. First, equipment error introduced by incorrectly sized cuffs or out-of-date BP machine 
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validation and calibration may contribute to inaccuracies.[9] Second, patient position and 
recent activities including caffeine ingestion, exercise, and smoking may impact 
measurements. Third, factors related to the dialysis vascular access and underlying vascular 
disease are also salient. While BP is typically taken in the arm opposite to the access, lower 
extremity BPs are measured when brachial measurements are not possible. Peripheral 
amplification of pulse pressure and poorly sized cuffs lead to higher lower extremity BP 
readings.[9] These potential measurement errors complicate not only chairside, clinical BP 
interpretation, but also create potential inaccuracies in research utilizing routinely measured 
dialysis unit BPs.
Even in studies where BP measurement technique is standardized and patient differences 
accounted for, in-center BP readings do not correlate well with ambulatory BPs.[10] Factors 
unique to the dialytic period including fluid and osmolar shifts and erythropoietin 
stimulating agents (ESA) affect cardiac output and BP. These dynamic conditions combined 
with high potential for measurement error limit the diagnostic capacity of in-center BPs. 
Despite these limitations, in-center BP measurements do have substantial clinical and 
prognostic importance, particularly in regard to identifying dynamic BP changes as we 
review below.
INTRADIALYTIC BLOOD PRESSURE PATTERNS
Observational studies of intradialytic BP patterns have identified extremes of BP fall, rise 
and fluctuations as important prognostic indicators. Pre- to post-dialysis BP change has been 
demonstrated to have a “J” or “U”-shaped mortality association in epidemiologic studies.
[4,5] In a recent analysis of over 110,000 patients, Park et al. reported a “U”-shaped 
association between mean pre- to post-HD systolic BP change and mortality. Authors found 
that peak survival was observed in patients with BP fall of 14 mmHg during HD. Patients 
with intradialytic BP falls >30 mmHg or BP rise >0 mmHg had greater mortality. In 
analyses stratified by pre-HD systolic BP, “U”-shaped associations between BP change and 
outcomes were found only in pre-HD systolic BP categories ≥120 mmHg. [5] Pre- to post-
HD BP change has important limitations as a prognostic metric, because it does not reflect 
individual intradialytic BP measurements such as nadir systolic BP. The measure thus falls 
short in accurately capturing intradialytic BP fluctuations of known clinical importance. 
Such intradialytic BP fluctuations are common. Blood pressure behavior during HD is 
influenced by a variety of physiologic and procedural factors including UF-driven fluid 
shifts, serum osmolality changes, neurohormonal axis and inflammatory pathway activation, 
and dialytic removal of antihypertensives and other vasoactive substances. High burdens of 
co-morbid disease and non-traditional cardiovascular risk factors such as stiff vasculature, 
impaired vasoreactivity, and autonomic dysfunction render dialysis patients particularly 
vulnerable to hemodynamic compromise from BP fluctuations.
In a study of intradialytic BPs in 218 patients across >2,000 HD treatments, Dinesh et al. 
characterized the intradialytic temporal trend of systolic BP behavior with a two slope linear 
spline. The model describes: 1) systolic BP at HD start, 2) a rapid decrease in systolic BP 
during the first 25% of treatment (slope of −25.5 ± 1.5 mmHg), and then 3) a more gradual 
decline in systolic BP in the latter 75% of treatment (slope of −5.8 ± 0.5 mmHg). Higher UF 
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volume and rate and calcium acetate use were associated with greater pre-HD BP and a 
more rapid decline in both early and late HD BP slopes.[11] Departures from this expected 
BP course include precipitous BP drops (intradialytic hypotension), pre- to post-dialysis BP 
elevation (intradialytic hypertension) and more subtle BP fluctuations (intradialytic BP 
variability), Figure 1. All three BP phenomena are associated with adverse clinical 
outcomes.
INTRADIALYTIC BLOOD PRESSURE FALL
Epidemiology and Definitions
Intradialytic hypotension is a well-recognized HD complication, occurring in 10–70% of 
treatments, depending on the definition.[12] Patient and clinical characteristics associated 
with intradialytic hypotension include older age, female sex, longer dialysis vintage, 
diabetes, lower pre-dialysis BP, lower albumin and higher body mass index.[12,13] Low BP 
during HD has been associated with a range of clinical and pathogenic consequences 
including inadequate dialysis dose, myocardial stunning, brain atrophy, vascular access 
thrombosis and increased mortality.[12,14–17] Surprisingly, we lack diagnostic criteria for 
intradialytic hypotension and consensus on optimal intervention thresholds.
Most clinical practice guidelines require the presence of symptoms or administration of 
interventions to fulfill intradialytic hypotension diagnostic criteria, but many epidemiologic 
studies associating hypotension with adverse outcomes are based on BP values alone. The 
National Kidney Foundation’s Kidney Disease Outcomes Quality Initiative (KDOQI) and 
European Best Practices Guidelines define intradialytic hypotension as a decrease in systolic 
BP ≥20 mmHg or a drop in mean arterial pressure (MAP) ≥10 mmHg during HD with 
associated symptoms.[18,19] In the Hemodialysis (HEMO) Study, intradialytic hypotension 
was defined as hypotension requiring either saline infusion or UF rate or blood flow 
reduction. Administrative research databases typically lack symptom and complete 
intervention data, necessitating definitions utilizing BP values alone. Such definitions are 
based on requisite BP falls (10–40 mmHg) or nadir intradialytic BP thresholds (60–100 
mmHg).[20–23] Other definition formulations combine requisite drops or thresholds with 
the presence of symptoms and/or interventions. For example, Chesterton et al. defined 
intradialytic hypotension with a nadir systolic BP <100 mmHg or a >10% intradialytic BP 
fall plus the presence of symptoms.[24] Unfortunately, definition discrepancies have limited 
data synthesis and hindered the development of evidence-based management guidelines.
Recently, Flythe et al. aimed to address the lack of uniform intradialytic hypotension 
diagnostic criteria by examining associations between commonly used definitions and 
mortality. This study clearly illustrates the influence of hypotension definition on prevalence 
estimates. Intradialytic hypotension defined as systolic BP fall >20 mmHg was observed in 
68% of treatments during the exposure period. In contrast, hypotension defined as systolic 
BP fall below 90 mmHg was present in only ~10% of exposure treatments. When outcomes 
were considered, nadir systolic BP of 90 mmHg was associated with greater all-cause 
mortality, adjusted HR (95% confidence interval; CI), 1.56 (1.05–2.31) in the HEMO Study 
cohort and 1.30 (1.07–1.57) in the large dialysis organization cohort. Other intradialytic 
hypotension definitions were not associated with mortality. Neither addition of symptoms 
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nor interventions to nadir-based definitions strengthened their associations with mortality.
[12] This finding stands in contrast to the existing clinical guideline intradialytic 
hypotension definitions that require symptoms or interventions.[18,19] In a recent 
prospective study, Meredith et al. demonstrated poor correlation between symptoms and 
nursing interventions for hypotension, further underscoring potential inaccuracy associated 
with symptom-based definitions.[25] Overall, existing data suggest a nadir-based 
intradialytic hypotension definition may be optimal for capturing mortality risk.
Pathophysiology
Maintenance of adequate blood volume during dialysis is dependent on multiple patient and 
HD factors. In absence of serious medical conditions such as infection, arrhythmias, 
pericardial tamponade, myocardial infarction, and hemorrhage and HD complications such 
as hemolysis, air embolism, and dialyzer reactions, intradialytic hypotension ensues when 
the pace of fluid removal exceeds the pace of plasma refill and associated physiologic 
compensatory responses. Decreased effective arterial blood volume during overly aggressive 
UF leads to decreased cardiac filling, decrements in cardiac output and, ultimately, 
hypotension. There are numerous patient, cardiovascular, volume, and HD treatment-related 
risk factors for intradialytic hypotension (Figure 2A). Compensatory mechanisms include 
increased cardiac output, enhanced plasma refill, passive venoconstriction and increases in 
arterial tone. Cardiac output is augmented by increased contractility and, to a lesser extent, 
increased heart rate.[26]
The pathophysiologic mechanisms underlying intradialytic hypotension provide insight into 
potential management strategies. Dialysate sodium, plasma albumin and the magnitude of 
hydrostatic capillary force all influence plasma refill. Exposure to higher dialysate—serum 
sodium gradients increase fluid mobilization into the intravascular space. Similarly, higher 
plasma osmolality, associated with greater albumin levels, enhances refill. Intradialytic 
osmolality decline from uremic toxin removal and sodium gradient equilibration lead to 
slowed vascular refill over the treatment course. Procedural factors such as warm dialysate, 
acetate buffer or eating during dialysis increase hypotension risk by decreasing peripheral 
resistance. Autonomic dysfunction and impaired baroreceptor sensitivity dampen the 
compensatory cardiac responses to these blood volume reductions.[27] Cardiac 
abnormalities such as diastolic dysfunction, atrial fibrillation, left ventricular hypertrophy, 
and ischemic heart disease also contribute. When compensatory responses for reduced 
cardiac filling reach their limits, BP falls.[26]
Furthermore, emerging data suggest that episodes of intradialytic hypotension beget future 
hemodynamic instability. Intradialytic hemodynamic compromise has been linked to 
episodic stunning of the myocardium.[14,15] Over time, repeat ischemia induces cardiac 
hypertrophy and fibrosis, further impairing response to decreased filling pressures and 
increasing risk for hemodynamic instability. Related, intradialytic gut hypoperfusion may 
increase systemic endotoxin levels. Endotoxemia is linked to chronic inflammation and 
cardiovascular risk via potentiation of pro-inflammatory cytokine generation, oxidative 
stress, and endothelial dysfunction.[28] Finally, hypoperfusion injury to the kidney may 
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accelerate the loss of native kidney function among patients with residual kidney function, 
an independent risk factor for mortality.[29]
Outcome Associations
Table 1 summarizes representative studies of intradialytic hypotension and mortality. While 
intradialytic hypotension is frequently cited as a mortality risk factor, observational studies 
have yielded mixed results. A 2003 Hungarian study found no association between 
intradialytic hypotension and mortality.[30] In contrast, a 2004 Japanese analysis 
demonstrated an association between intradialytic hypotension and greater mortality with 
lower nadir systolic BP associating with higher all-cause death risk.[31] In 2014, Stefánsson 
et al. examined the relationship between intradialytic hypotension and all-cause mortality 
and a composite outcome of myocardial infarction, stroke, and cardiovascular mortality in a 
U.S. cohort, finding associations with both.[32] These discrepant findings may, in part, be 
explained by differences in hypotension definitions and number of HD treatments used to 
identify hypotensive episodes. The Japanese study considered only one HD treatment, 
whereas the Hungarian and U.S. analyses classified intradialytic hypotension over longer 
periods, 10 months and 90 days, respectively. In a two cohort observational analysis, Flythe 
et al. demonstrated an association between intradialytic nadir systolic BP <90 mmHg and 
all-cause mortality. These findings were robust in both cohorts and across varying levels of 
pre-HD systolic BP.[12] Beyond mortality, intradialytic hypotension has been associated 
with vascular access thrombosis and mesenteric ischemia.[16,22]
Studies considering the associations of BP fall and intermediate outcomes link 
hemodynamic insults to a range of adverse end-organ sequelae including cardiac ischemia, 
gut ischemia and structural brain changes. In two studies Burton et al. describe greater 
intradialytic BP fall among patients with cardiac ischemia as evidenced by myocardial wall 
stunning on echocardiography.[15,33] However, simultaneous assessments of BP and 
echocardiography limit causality inferences. Troponin elevations over the course of dialysis 
further supports HD treatment-associated cardiac ischemia.[34] Second, hypotension has 
been linked to gut ischemia. Interruptions to bowel perfusion can result in endotoxin 
translocation to the bloodstream. A study by McIntyre and colleagues reported elevated 
blood endotoxin levels among HD patients with greater intradialytic BP fall.[28] Finally, 
hypoperfusion-induced brain injury among HD patients may also contribute to adverse 
outcomes.[17] Firm conclusions about the associations of and causal pathways between 
intradialytic hypotension and these intermediate outcomes are limited by the use of cross-
sectional study designs, small sample sizes and potential residual confounding from factors 
such as low pre-HD blood pressure, diabetes, co-morbid cardiac disease, and 
hypoalbuminemia not accounted for in these descriptive studies. Despite their limitations, 
these mechanistic investigations provide compelling evidence supporting associations of 
intradialytic hemodynamic instability and intermediate, non-fatal outcomes including 
hypoperfusion-induced heart, gut, and brain insults.
Management
Frank symptomatic hypotension mandates swift nursing intervention. Acute management 
may include stopping UF or HD entirely, placing the patient in the Trendelenburg position, 
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and/ or administering intravenous fluid and supplemental oxygen. Intervention selection is 
typically driven by event severity and is left to clinical judgement. Evidence supporting BP 
thresholds for intervention and optimal approaches for BP restoration are limited. For 
intravascular volume repletion, most clinicians rely on isotonic saline but options include 
hypertonic saline, hypertonic glucose, 5% dextrose, and albumin. Use of albumin is 
expensive, and a small randomized trial suggested equivalence between saline and albumin.
[35] Hypertonic glucose may be the most effective at restoring blood volume, but use is 
limited by the high diabetes prevalence among HD patients.[36] Once hemodynamic 
stability is restored, attention turns to ruling out causative procedural complications such as 
hemolysis, air embolus and dialyzer reactions. Non-procedural causes such as pericardial 
tamponade, cardiac ischemia, hemorrhage and infection should be assessed via history and 
examination. In cases where BP is not responsive to interventions or when hypotension is 
accompanied by chest or abdominal pain, dyspnea or fever, patients may require hospital 
evaluation for cardiac ischemia, sepsis, and occult bleeding.
While restoration of the circulatory volume is the priority during episodes of intradialytic 
hypotension, downstream consequences of interventions such as fluid administration, target 
weight adjustment and dialysate sodium adjustment should not be discounted. First, patients 
with frequent hypotension are at risk for recurrent target weight misses and chronic volume 
overload. Both of these clinical scenarios are associated with mortality.[37,38] Clinical 
experience reveals that target weights are often adjusted upward to “match” achieved post-
weights following hypotension. In these cases clinicians assume the target weight is 
underestimated. While target weight adjustment is occasionally required, it is the authors’ 
opinion that weight change should not be the default response to hypotensive episodes.[39] 
Hypotensive events often reflect a mismatch in UF and refill rates rather than total body 
volume depletion. Unfortunately, we lack objective measures to help distinguish these 
situations. Clinical clues such as the intradialytic timing of the hypotensive event and tools 
such as blood volume monitors may be helpful.[40] Hypotension early in HD may reflect 
preexisting hypovolemia and should prompt reassessment of target weight, while late 
treatment hypotension may represent either an excessive UF rate or target weight over-
estimation. Other precipitants also remain plausible. Second, hypertonic saline 
administration (and to a lesser extent, isotonic saline) and use of wide dialysate—serum 
sodium gradients lead to sodium loading, a risk factor for interdialytic thirst and subsequent 
interdialytic weight gain (IDWG).[41,42] Greater IDWG is associated with more frequent 
intradialytic hypotension and greater cardiovascular morbidity and mortality.[43] Related, 
sodium modeling, an effective hypotension preventive maneuver, has been rendered 
obsolete due to associated sodium loading.[41] Ultimately, clinicians must balance the risk 
of future hypotensive events against the risk of volume overload.
Acute hypotensive episodes should be contextualized in the patient’s recent clinical history. 
Data demonstrate a dose-response association between intradialytic hypotension and 
mortality: more frequent hypotension is associated with an incrementally greater risk of 
death.[12] Preventive strategies should be considered in patients with recurrent hypotension. 
The European Best Practice Guidelines for intradialytic hypotension prevention are 
presented in Table 2.[19] Preventative strategies should be accompanied by a medication 
review with focus on dosing and timing of antihypertensives, opiates, and other sedating 
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medications. Evaluation for underlying ischemic heart disease and heart failure may be 
indicated.
Definitive, evidence-based intradialytic hypotension prevention strategies are few. Dialysate 
cooling has the best efficacy data with randomized trial data showing decreased brain white 
matter changes with cooled dialysate and a systematic review of 22 studies finding clinical 
benefit to cooled dialysate.[44,45] However, formal assessments of patient tolerance and 
preference are lacking. Dialysis treatment time extension or additional HD treatments to 
facilitate more gradual fluid removal is helpful for some patients, but implementation of 
these strategies are limited by patient acceptance.[46] Additional HD treatment-related 
hypotensive preventive strategies include: UF modeling, the practice of varying the UF rate 
during HD, and sequential dialysis, the practice of isolated UF followed by UF plus HD. 
Both practices are intended to match UF to plasma refill rates by maximizing UF at times of 
greatest hydration and oncotic pressure, but neither practice has been well-studied. Finally, 
dialysate composition changes can be considered. Increased dialysate calcium may improve 
hemodynamic stability through augmented cardiac contractility, but concerns about calcium 
balance limit widespread use.[47]
In patients with recurrent hypotension despite preventative measures, addition of midodrine, 
a selective alpha-1 adrenergic agonist, may be considered. A systematic review of 10 studies 
and 117 patients found that compared with control, midodrine was associated with increased 
nadir and post-HD systolic BPs.[48] Midodrine is typically dosed 15–30 minutes before 
dialysis but dosing may be split into pre-HD and mid-HD doses to help mitigate late 
treatment hypotension. Vigilance for side effects including urinary retention, supine 
hypotension, and pruritus is warranted.[48] The supplement L-carnitine has not proven 
effective in preventing intradialytic hypotension.[49] Less well-studied preventative 
medications include sertraline and vasopressin.[50,51] Among patients with refractory, 
recurrent hypotensive episodes, change to peritoneal, nocturnal, or daily dialysis may be 
warranted.
INTRADIALYTIC BLOOD PRESSURE RISE
Epidemiology and Definitions
While less common than intradialytic hypotension, intradialytic hypertension is another BP 
phenomenon with important prognostic significance. Patient and clinical characteristics 
associated with intradialytic BP rise include older age, lower body weight, lower serum 
creatinine and albumin, and utilization of more antihypertensive medications.[52,53] The 
prevalence of intradialytic hypertension ranges 5–15% among maintenance HD patients, 
depending on the definition.[54,55] Currently, there is no universally accepted definition of 
intradialytic hypertension. It is typically defined as BP increase during or immediately after 
HD, resulting in post-HD BP >130/80 mmHg, the KDOQI hypertension threshold.[54] 
Clinical investigations of this BP abnormality have used a range of definitions with varied 
thresholds of systolic BP or MAP increase (≥10 or 15 mmHg).[52] Others have selected 
more general definitions such as hypertension late in dialysis after the occurrence of the 
majority of UF or BP rise resistant to UF.[56] Some definitions are limited to 
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subpopulations such as patients with de novo hypertension with ESA initiation, narrowing 
generalizability.[57]
Pathophysiology
The pathophysiology underlying paradoxical intradialytic BP rise is not fully understood, 
but data suggest interplay among positive sodium balance, volume overload, activation of 
the renin-angiotensin-aldosterone (RAAS) and sympathetic nervous systems, hemodialytic 
removal of antihypertensives, endothelial cell dysfunction, erythropoiesis-stimulating agents 
(ESA), and bone mineral disease axis abnormalities (Figure 2B). Hypervolemia is a well-
recognized risk factor for hypertension among HD patients and is the cause of intradialytic 
hypertension in a subset of patients.[58,59] In one study, additional UF reduced cardiac 
dilation on echocardiography and lowered cardiac index and MAP.[58] However, factors 
beyond volume overload are important mediators of intradialytic hypertension in many 
patients.
Sympathetic nervous system over-activity, RAAS activation and associated vasoconstriction 
are plausible contributors. However, patients with intradialytic hypertension experience an 
intradialytic rise in systemic vascular resistance without a consistent, concurrent increase in 
catecholamine or renin levels, signifying that other mechanisms may drive the development 
of intradialytic hypertension.[60] In addition, Other contributors to intradialytic 
hypertension include dialytic removal of antihypertensive medications (e.g. atenolol, 
metoprolol, and angiotensin converting enzyme (ACE) inhibitors) and a positive calcium 
balance conferred from higher dialysate calcium concentrations.[54]
Recent investigations have established endothelial cell dysfunction as a key mediator in 
intradialytic hypertension. Endothelial cells contribute to BP homeostasis by synthesizing 
and releasing humoral factors such as nitric oxide, a smooth muscle vasodilator, and 
endothelin-1, a vasoconstrictor. Among patients with intradialytic hypertension, studies have 
demonstrated that endothelin-1 levels rise during dialysis while systemic nitric oxide levels 
remain inappropriately low.[60,62] Erythropoietin stimulating agents may contribute to 
intradialytic hypertension via this mechanism.[63] The role of impaired endothelial cell 
response to HD is further supported by studies demonstrating a decrease in intradialytic 
hypertension frequency in response to the beta blocker carvedilol, a medication that 
suppresses endothelin-1 release in vitro.[64] Additionally, greater dialysate sodium may 
contribute to intradialytic hypertension through two mechanisms: enhanced IDWG and 
stimulated release of endothelial-derived vasoregulators. A small crossover trial 
demonstrated lower mean BPs with use of lower dialysate sodium but no change in 
intradialytic endothelin-1 or nitric oxide levels. Authors postulated that carryover effects 
from the study arms may have inhibited detection of vasoregulators changes.[65]
Outcome Associations
Paradoxical intradialytic BP rise has been noted for decades, but its association with 
cardiovascular morbidity and mortality has only recently been recognized. Table 3 provides 
an overview of studies investigating intradialytic hypertension and mortality associations. In 
a post hoc analysis of the Crit-line Intradialytic Monitoring Benefit Study (CLIMB) Study, 
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Inrig and colleagues found that patients whose BP rose or failed to lower with HD had a two 
times the odds of non-vascular access related hospitalization or death at 6-months compared 
to patients with pre- to post-HD BP fall.[52] In an incident HD cohort, Inrig et al. found that 
every 10 mmHg increase in systolic BP during HD was independently associated with 
increased mortality, HR (95% CI): 1.12 (1.05–1.21). The risk associated with intradialytic 
hypertension was magnified in patients with low pre-HD systolic BP (<120 mmHg), raising 
the possibility of residual confounding from ambient health status.[53] The associations of 
intradialytic hypertension and adverse outcomes are also supported by results from a 
prospective Taiwanese study showing an association between pre- to post-HD BP rise >5 
mmHg and mortality.[66] Finally, in a non-outcomes-based study, Van Buren et al. 
demonstrated that HD patients with intradialytic hypertension have higher interdialytic BPs, 
providing evidence of an enhanced cumulative hypertensive burden that may contribute to 
accelerated left ventricular hypertrophy and associated adverse cardiovascular events.[67]
Management
The proposed pathophysiology underlying intradialytic hypertension is multifactorial and, as 
such, presents several targets for intervention. Potential interventions include those aimed at 
mitigating volume overload, sympathetic over-activity, RAAS activation and endothelial 
cell dysfunction. Other strategies include antihypertensive medication and dialysate 
composition changes. As chronic volume overload is linked to an array of adverse 
cardiovascular consequences in HD patients, the first-line approach for the treatment of 
intradialytic hypertension is likely judicious target weight reduction. Increased UF and 
careful target weight reduction have been shown to improve intradialytic hypertension.[58] 
Related, dietary salt intake should be restricted as a means to reduce IDWG. While these 
interventions will not resolve intradialytic hypertension in all patients, BP improvement in 
some patients is to be expected. However, volume challenges may exacerbate intradialytic 
hypertension in some patients as some data suggest over-activation of the RAAS and 
sympathetic nervous system in response to UF and associated cardiac preload reduction.[68]
For patients not responsive to volume challenge, medication regimens should be carefully 
reviewed. Withholding antihypertensives prior to dialysis is a common practice and should 
be reconsidered in patients with intradialytic hypertension. Highly dialyzable 
antihypertensive drugs should be avoided or dosed post-dialysis. In addition, ESA dosage 
should be reduced as much as safely possible and subcutaneous administration considered. 
Second, pharmaceutical interventions such as adrenergic blockers may be effective among 
patients with chronic intradialytic hypertension. Beta-blockers with alpha-receptor activity, 
such as carvedilol, are non-dialyzable and have been shown to reduce intradialytic 
hypertension, likely via their pleiotropic effects on endothelial cells. In a prospective, 12-
week, pilot crossover study of 25 HD patients with intradialytic hypertension, treatment with 
carvedilol 50 mg twice daily reduced post-HD BP, 44 hour ambulatory BP, and frequency of 
intradialytic hypertension episodes. Modest improvements in endothelial cell dysfunction 
were also demonstrated.[64] Ultrafiltration-induced activation of the RAAS may also 
contribute to intradialytic hypertension, suggesting that ACE inhibitors or angiotensin 
receptor blockers (ARBs) may be effective.[61] As the majority of ACE inhibitors are 
dialyzable, ARBs may be better choices for patients with intradialytic hypertension.
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Finally, dialysate prescription alterations may reduce intradialytic hypertension. Positive 
sodium balance is associated with thirst, IDWG and subsequent volume-mediated 
hypertension as well as endothelial dysfunction and associated endothelin-1—nitric oxide 
imbalance. HD prescription strategies aimed at reduction of serum sodium and the dialysate
—serum sodium gradient may be beneficial. This hypothesis was recently tested in a 3 
week, 2-arm randomized, crossover study in which 16 HD patients with intradialytic 
hypertension were randomized to low versus high dialysate-serum sodium gradients. Low 
dialysate sodium concentrations (5 meq/L below serum sodium) were associated with 
decreased mean BPs.[65] Finally, high dialysate calcium prescriptions should be avoided in 
patients without hypocalcemia as a means to limit intradialytic hypertension from calcium-
enhanced cardiac contractility.
INTRADIALYTIC BLOOD PRESSURE VARIABILITY
Epidemiology, Definitions, and Outcome Associations
While both hypotension and hypertension are well-established risk factors for adverse 
outcomes, BP deviation from the expected course, termed BP variability, has recently come 
to light as a prognostic factor. The majority of BP variability studies in the general and HD 
populations have considered long-term, visit-to-visit BP variability, measured at clinical 
visits across days, weeks, or months. In the general population, greater long-term BP 
variability is associated with stroke, heart disease, and mortality.[69] Among HD patients, 
long-term BP variability is measured with pre-HD BPs on a HD treatment-to-treatment basis 
and is associated with cardiovascular morbidity and mortality.[70,71] Recent data suggests 
that short-term BP variability, considered as intradialytic BP fluctuations, is a cardiovascular 
risk factor among HD patients.[72] While some BP fluctuations in response to changing 
physiologic conditions are to be expected during dialysis, marked deviation from the 
expected intradialytic BP course is associated with adverse outcomes and is relevant to this 
review.
Intradialytic BP variability refers to BP fluctuations that are independent of other BP 
phenomena occurring during dialysis. This important distinction prevents conflation of the 
prognostic significance of BP fluctuations during HD with that of other intradialytic BP 
abnormalities. When considering intradialytic BP fluctuations, BP variability must be 
independent of pre-HD systolic BP and the expected biphasic intradialytic BP decline. 
Blood pressure variability can be defined by several metrics including standard deviation, 
absolute real variability, residuals derived from linear models, and others. Residuals derived 
from linear mixed models with a spline function have been used to describe intradialytic 
systolic BP variability as they capture fluctuations from the expected 2-slope intradialytic 
BP course. Patient and procedural factors associated with variability from this expected 
course include older age, heart failure, heart disease, diabetes, greater UF volume, more 
rapid UF rates, and larger IDWG.[73]
In a study of 6,393 prevalent HD patients using absolute regression residuals from a linear 
effects model with a 2-slope spline, Flythe et al. demonstrated an association between 
greater intradialytic systolic BP variability and increased all-cause and cardiovascular 
mortality. High BP variability (defined as an absolute systolic BP residual >8.7 mmHg, the 
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cohort median) was associated with a 32% higher hazard of death (p=0.04) compared to low 
BP variability. When BP variability was considered in quartiles, dose-response relationships 
between BP variability and all-cause (p=0.001) and cardiovascular (p=0.04) mortality were 
observed.[72] While this study provides strong support for an association between increased 
intradialytic BP variability and mortality, it is the sole investigation on this topic.
Pathophysiology and Management
In general, the pathophysiology of BP variability is not well-defined, but there are several 
plausible mediators. Impaired endothelial function, heightened inflammation, increased 
vessel wall stress, baroreceptor dysfunction, and enhanced sympathetic nervous system 
activity are all potential contributors to BP variability.[74] Among dialysis patients, HD 
treatment fluid and osmolar shifts promote random BP fluctuations. Stiff vasculature, 
reduced cardiac output, autonomic dysfunction, and neurohormonal imbalance common 
among HD patients may amplify these fluctuations and engender vulnerability to 
hemodynamic changes. Thus, BP fluctuations may induce subclinical end-organ 
hypoperfusion and subject patients to alternating periods of tissue hypoxia and capillary 
shear stress.
Recommendations regarding management of intradialytic BP variability are non-existent 
due to two key limitations: 1) lack of a clinically accessible chairside measure and 2) 
absence of studies investigating effective intervention strategies. First, to adequately 
distinguish intradialytic BP variability from the expected temporal BP course during HD, 
complex analytical approaches must be employed. The existing BP variability metrics are 
not easily calculated and are appropriate for research, not clinical settings. Thus, clinicians 
have no way to objectively classify BP variability. Second, clinical outcomes data for 
intradialytic variability is limited to a single study. This evidence suggests that risk factors 
for short-term (intradialytic) BP variability and long-term (visit-to-visit) BP variability may 
differ. Shafi et al. demonstrated that greater UF was associated with less long-term (visit-to-
visit) BP variability, but Flythe et al. reported that greater UF was associated with greater 
short-term (intradialytic) BP variability.[71,73] These conflicting findings are not surprising 
given the differences in hemodynamic environments of the intra- and interdialytic periods. 
Prior to making recommendations about management of intradialytic BP variability, the 
relative importance of long-term (visit-to-visit) and short-term (intradialytic) BP variability 
among dialysis patients must be established and investigations examining mitigation 
strategies such as changes in fluid removal practice or perhaps antihypertensive agent 
selection must be conducted. Until then, it is prudent to minimize large BP fluctuations 
during dialysis by carefully monitoring hemodynamics, volume status and medication 
effects.
CONCLUSION
Existing observational studies provide compelling data supporting associations between 
intradialytic BP phenomena including hypotension, hypertension, and variability and clinical 
outcomes. Unfortunately, the evidence base for effective management strategies of these 
dynamic BP changes is weak overall. We lack prospective studies, including randomized 
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trials, confirming optimal diagnostic criteria, evaluating BP thresholds for intervention, 
assessing the clinical benefit of different intervention strategies, and comparing preventative 
strategies. Table 4 provides an overview of evidence gaps that provide fertile ground for 
future research.
Despite these evidence limitations and clinical uncertainties, numerous peridialytic and 
intradialytic BP measurements confront dialysis unit staff and clinicians during HD 
administration. Emerging data suggest that vigilance for hemodynamic fluctuations beyond 
those associated with overt symptoms is prudent, adding further nuance and complexity to 
chairside BP interpretation and management. To confront this challenge, providers must 
draw upon their longitudinal patient relationships, enriched by knowledge about historical 
BP trends, treatment tolerance, volume status, prescription medications, and health status 
garnered from frequent, attentive patient visits during dialysis. Careful volume assessment 
through physical examination, interdialytic BP evaluation, and HD treatment response, 
supplemented by data from blood volume monitors and bioimpedance, when available, is 
paramount. Until prospective studies elucidate the optimal management approaches to 
intradialytic hypotension, hypertension, and variability, individualized prescriptions of 
antihypertensives, dialysate composition and fluid removal along with close hemodynamic 
monitoring are the most appropriate therapeutic approaches to limit harm from intradialytic 
BP fluctuations.
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Patterns of intradialytic blood pressure behavior.
Abbreviations: BP, blood pressure.
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Pathophysiology of intradialytic hypotension (panel A) and hypertension (panel B).
Abbreviations: HD, hemodialysis.
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Table 2
Clinical guidelines for intradialytic hypotension prevention.[19]
First-line
  Dietary counselling (sodium restriction)
  Avoidance of food ingestion during dialysis
  Clinical reassessment of target weight
  Use of bicarbonate dialysis buffer
  Use of dialysate temperature of 36.5°C
  Review of dosing and timing of antihypertensives
Second-line
  Objective measures for reassessment of target weight
  Cardiac evaluation
  Gradual reduction of dialysate temperature (lowest 35°C)
  Individualized blood volume controlled feedback
  Increased dialysis treatment time or extra treatment
Third-line
  Midodrine
  L-carnitine supplementation
  Dialysis modality change
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Table 4
Knowledge gaps regarding intradialytic blood pressure abnormalities.
Intradialytic hypotension and hypertension
  Evidence-based definitions and thresholds for intervention
  Objective volume status measures including roles of bioimpedance and blood volume monitoring
  Efficacy of ultrafiltration profiling and sequential ultrafiltration + dialysis in preventing BP falls and rises
  Identification of optimal dialysate—serum sodium gradient differentials
  Development of evidence-based prevention protocols
  Development of evidence-based treatment protocols
  Prospective evaluations of pathophysiologic mechanisms to confirm cross-sectional study findings
Intradialytic blood pressure variability
  Evidence-based definition and thresholds for intervention
  Clinically accessible measure and assessment tool
  Effective mitigation strategies
  Confirmation of observational study results in prospective patient cohorts
Abbreviations: BP, blood pressure
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